PARP inhibition can enhance innate immunity through various mechanisms, leading to the development of combination treatments with PARPi and immunotherapy for the treatment of cancers, including solid tumors and hematologic malignancies (Ding et al., 2018; Kim et al., 2020). The gene discussed is PARP1; the disease is cancer.